STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The company is headquartered in Monrovia California, California and currently employs 1,157 full-time employees. The firm markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The firm's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). The company also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. The company makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Mr. Stephen Farrell is the Chief Executive Officer of STAAR Surgical Co, joining the firm since 2016.
What is the price performance of STAA stock?
The current price of STAA is $18.05, it has decreased 0.16% in the last trading day.
What are the primary business themes or industries for STAAR Surgical Co?
STAAR Surgical Co belongs to Health Care industry and the sector is Health Care
What is STAAR Surgical Co market cap?
STAAR Surgical Co's current market cap is $897.8M
Is STAAR Surgical Co a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for STAAR Surgical Co, including 2 strong buy, 4 buy, 11 hold, 0 sell, and 2 strong sell